Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2290883 | 0.88 | HIF1A (0.66) | HIF1ASLC29A1 | |
| SCHEMBL2290876 | 0.88 | HIF1A (0.66) | HIF1ASLC29A1 | |
| SCHEMBL23648131 | 0.88 | SLC29A1 (0.65) | HIF1ASLC29A1 | |
| SCHEMBL1042589 | 0.87 | POLB (0.54) | SLC29A1 | |
| SCHEMBL8180881 | 0.86 | SLC29A1 (0.63) | HIF1ASLC29A1 | |
| SCHEMBL8180887 | 0.86 | SLC29A1 (0.63) | HIF1ASLC29A1 | |
| SCHEMBL2288246 | 0.86 | HIF1A (0.68) | HIF1ASLC29A1ADORA3 | |
| SCHEMBL2288240 | 0.86 | HIF1A (0.68) | HIF1ASLC29A1ADORA3 | |
| SCHEMBL5849139 | 0.85 | SLC29A1 (0.69) | HIF1ASLC29A1ADORA3ADORA1 | |
| SCHEMBL5849132 | 0.85 | SLC29A1 (0.69) | HIF1ASLC29A1ADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110300170-A1 | HCV VACCINES | INTERCELL AG (AT) | 2011-12-08 | — | — | US | claimed |
| US-20110236414-A1 | Bacterial Polysaccharide-Polypeptide Conjugate Compositions | INTERCELL AG (AT) | 2011-09-29 | — | — | US | claimed |
| EP-2345420-A1 | Use of a TH1 immune response inducing adjuvant for enhancing immune responses | Intercell AG (AT) | 2011-07-20 | — | — | EP | claimed |
| EP-2313116-A1 | IMPROVED BACTERIAL POLYSACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS | Intercell AG (AT) | 2011-04-27 | — | — | EP | claimed |
| JP-4676426-B2 | — | — | 2011-04-27 | — | — | JP | claimed |
| EP-2275131-A2 | HCV Vaccines | Intercell AG (AT) | 2011-01-19 | — | — | EP | claimed |
| US-7858588-B2 | Immunostimulatory oligodeoxynucleic molecules | INTERCELL AG (AT) | 2010-12-28 | — | — | US | claimed |
| EP-1648502-B1 | HCV VACCINES | INTERCELL AG (AT) | 2010-12-01 | — | — | EP | claimed |
| US-20100297170-A1 | VACCINES | VALNEVA AUSTRIA GMBH (AT) | 2010-11-25 | — | — | US | claimed |
| WO-2010015701-A1 | IMPROVED BACTERIAL POLYSACCHARIDE-POLYPEPTIDE CONJUGATE COMPOSITIONS | INTERCELL AG (AT) | 2010-02-11 | — | — | WO | claimed |
| US-20040248831-A1 | Immunostimulatory oligodeoxynucleic molecules | INTERCELL AG (AT) | 2004-12-09 | — | — | US | claimed |
| WO-2004084938-A1 | IMPROVED VACCINES | INTERCELL AG (AT) | 2004-10-07 | — | — | WO | claimed |
| EP-1450821-A1 | IMMUNOSTIMULATORY OLIGODEOXYNUCLEOTIDES | Intercell AG (AT) | 2004-09-01 | — | — | EP | claimed |
| EP-1390495-A2 | IMMUNOSTIMULATORY OLIGODEOXYNUCLEIC MOLECULES | Intercell AG (AT) | 2004-02-25 | — | — | EP | claimed |
| EP-1296713-B1 | IMMUNOSTIMULATORY OLIGODEOXYNUCLEOTIDES | INTERCELL BIOMEDIZINISCHE FORSCHUNGS & ENTWICKLUNGS GMBH (AT) | 2003-09-17 | — | — | EP | claimed |
| US-20030171321-A1 | Immunostimulatory oligodeoxynucleotides | VALNEVA AUSTRIA GMBH (AT) | 2003-09-11 | — | — | US | claimed |
| WO-2003047602-A1 | IMMUNOSTIMULATORY OLIGODEOXYNUCLEOTIDES | INTERCELL AG (AT) | 2003-06-12 | — | — | WO | claimed |
| EP-1296713-A1 | IMMUNOSTIMULATORY OLIGODEOXYNUCLEOTIDES | Cistem Biotechnologies GmbH (AT) | 2003-04-02 | — | — | EP | claimed |
| WO-2002095027-A2 | IMMUNOSTIMULATORY OLIGODEOXYNUCLEIC MOLECULES | INTERCELL AG (AT) | 2002-11-28 | — | — | WO | claimed |
| WO-2001093905-A1 | IMMUNOSTIMULATORY OLIGODEOXYNUCLEOTIDES | INTERCELL BIOMEDIZINISCHE FORSCHUNGS- UND ENTWICKLUNGS AG (AT) | 2001-12-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300170-A1 | HCV VACCINES | HAVCR2, CXCR3, CD81 | HIF1A 1683/4885SLC29A1 3965/4885ADORA3 4418/4885 |
| US-20100297170-A1 | VACCINES | DDX1, DHX15, DDX5 | HIF1A 2222/4885SLC29A1 254/4885ADORA3 763/4885 |
| US-20040248831-A1 | Immunostimulatory oligodeoxynucleic molecules | NT5C3B, UMPS, NT5C2 | HIF1A 3665/4885SLC29A1 75/4885ADORA3 163/4885 |
| US-20110236414-A1 | Bacterial Polysaccharide-Polypeptide Conjugate Compositions | DDOST, NGLY1, DAD1 | HIF1A 3242/4885SLC29A1 686/4885ADORA3 537/4885 |
| US-20030171321-A1 | Immunostimulatory oligodeoxynucleotides | NT5C3B, PNP, UMPS | HIF1A 3698/4885SLC29A1 113/4885ADORA3 235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.